International Journal of Antimicrobial Agents
Volume 36, Issue 2 , Pages 132-136 , August 2010

Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria

  • James Carroll

      Affiliations

    • Department of Biological Sciences, Cork Institute of Technology, Cork, Ireland
    • ,
  • Lorraine A. Draper

      Affiliations

    • Department of Microbiology, University College Cork, College Road, Cork, Ireland
    • ,
  • Paula M. O’Connor

      Affiliations

    • Moorepark Food Research Centre, Teagasc, Moorepark, Fermoy, Co. Cork, Ireland
    • ,
  • Aidan Coffey

      Affiliations

    • Department of Biological Sciences, Cork Institute of Technology, Cork, Ireland
    • ,
  • Colin Hill

      Affiliations

    • Department of Microbiology, University College Cork, College Road, Cork, Ireland
    • Alimentary Pharmabiotic Centre, Cork, Ireland
    • ,
  • R. Paul Ross

      Affiliations

    • Moorepark Food Research Centre, Teagasc, Moorepark, Fermoy, Co. Cork, Ireland
    • Alimentary Pharmabiotic Centre, Cork, Ireland
    • ,
  • Paul D. Cotter

      Affiliations

    • Moorepark Food Research Centre, Teagasc, Moorepark, Fermoy, Co. Cork, Ireland
    • Alimentary Pharmabiotic Centre, Cork, Ireland
    • ,
  • Jim O’Mahony

      Affiliations

    • Department of Biological Sciences, Cork Institute of Technology, Cork, Ireland
    • Corresponding Author InformationCorresponding author. Tel.: +353 21 432 6833.

Received 16 February 2010 ,Accepted 25 March 2010.

References 

  1. World Health Organization. Global tuberculosis control—epidemiology, strategy, financing. WHO report 2009. Geneva, Switzerland: WHO; 2009. WHO/HTM/TB/2009.411.
  2. Tomioka H, Namba K. Development of antituberculous drugs: current status and future prospects. Kekkaku. 2006;12:753–774
  3. Field SK, Cowie RL. Lung disease due to the more common nontuberculous mycobacteria. Chest. 2006;129:1653–1672
  4. Hermon-Taylor J, Bull TJ, Sheridan JM, Cheng J, Stellakis ML, Sumar N. Causation of Crohn's disease by Mycobacterium avium subspecies paratuberculosis. J Gastroenterol. 2000;6:521–539
  5. Scanu AM, Bull TJ, Cannas S, Sanderson JD, Sechi LA, Dettori G, et al. Mycobacterium avium subspecies paratuberculosis infection in cases of irritable bowel syndrome and comparison with Crohn's disease and Johne's disease: common neural and immune pathogenicities. J Clin Microbiol. 2007;12:3883–3890
  6. Nacy C, Buckley M. Mycobacterium avium paratuberculosis: infrequent human pathogen or public health threat? August 2008. Washington, DC: American Academy of Microbiology; 2008;
  7. Williams B, Neth O, Shingadia D, Dixon G, Jupp RS, Rosendahl K, et al. Mycobacterium kansasii causing septic arthritis and osteomyelitis in a child. Pediatr Infect Dis J. 2010;1:88–89
  8. Cotter PD, Hill C, Ross RP. Bacterial lantibiotics: strategies to improve therapeutic potential. Curr Protein Pept Sci. 2005;6:61–75
  9. Parisien A, Allain B, Zhang J, Mandeville R, Lan CQ. Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J Appl Microbiol. 2008;104:1–13
  10. Russell JB, Mantovani HC. The bacteriocins of ruminal bacteria and their potential as an alternative to antibiotics. J Mol Microbiol Biotechnol. 2002;4:347–355
  11. Gillor O, Nigro LM, Riley MA. Genetically engineered bacteriocins and their potential as the next generation of antimicrobials. Curr Pharm Des. 2005;11:1067–1075
  12. Asaduzzaman SM, Sonomoto K. Lantibiotics: diverse activities and unique modes of action. J Biosci Bioeng. 2009;5:475–487
  13. Willey JM, van der Donk WA. Lantibiotics: peptides of diverse structure and function. Annu Rev Microbiol. 2007;61:477–501
  14. Bierbaum G, Sahl HG. Lantibiotics: mode of action, biosynthesis and bioengineering. Curr Pharm Biotechnol. 2009;10:2–18
  15. Delves-Broughton J. Nisin and its application as a food preservative. J Soc Dairy Technol. 1990;43:73–76
  16. Morgan S, O’Connor P, Cotter P, Ross RP. Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations. Antimicrob Agents Chemother. 2005;49:2606–2611
  17. Piper C, Draper LA, Cotter PD, Ross PR, Hill C. A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother. 2009;64:546–551
  18. Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B, et al. Specific binding of nisin to peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem. 2001;276:1772–1779
  19. Breukink E, Wiedemann I, van Kraaij C, Kuipers OP, Sahl H, de Kruijff B, et al. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science. 1999;17:2361–2364
  20. Brötz H, Josten M, Wiedemann I, Schneider U, Götz F, Bierbaum G, et al. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol Microbiol. 1998;30:317–327
  21. Wiedemann I, Bottiger T, Bonelli RR, Wiese A, Hagge SO, Gutsmann T, et al. The mode of action of the lantibiotic lacticin 3147—a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol Microbiol. 2006;61:285–296
  22. Hartmann GR, Heinrich P, Kollenda MC, Skrobranek B, Tropschug M, Weib W. Molecular mechanism of action of the antibiotic rifampicin. Angew Chem Int Ed Engl. 2003;24:1009–1014
  23. Mahapatra S, Yagi T, Belisle JT, Espinosa BJ, Hill PJ, McNeill MR. Mycobacterial lipid II is composed of a complex mixture of modified muramyl and peptide moieties linked to decaprenyl phosphate. J Bacteriol. 2005;187:2747–2757
  24. Montville TJ, Chung HJ, Chikindas ML, Chen Y. Nisin A depletes intracellular ATP and acts in a bactericidal manner against Mycobacterium smegmatis. Lett Appl Microbiol. 1999;28:189–193
  25. Field D, O’Connor PM, Cotter PD, Hill C, Ross RP. The generation of nisin variants with enhanced activity against specific Gram-positive pathogens. Mol Microbiol. 2008;69:218–230
  26. Bastian I, Rigouts L, Palomino JC, Portaels F. Kanamycin susceptibility testing of Mycobacterium tuberculosis using Mycobacterium Growth Indicator Tube and a colorimetric method. Antimicrob Agents Chemother. 2001;45:1934–1936
  27. Franzblau SG, Witzig RS, McLaughlin JC, Torres P, Madico G, Hernandez A, et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate alamarBlue assay. J Clin Microbiol. 1998;36:362–366
  28. Carroll J, Douarre P, Coffey A, Buckley J, Cashmen B, O’Farrell K, et al. Optimisation of a rapid viability assay for Mycobacterium avium paratuberculosis (MAP) using alamarBlue. Appl Environ Microbiol. 2009;75:7870–7872
  29. alamarBlue® technical datasheet. Oxford, UK: AbD Serotec; 2008. http://www.biokom.com.pl/files/alamarblue.pdf [accessed 22 April 2010].
  30. Zaiou M. Multifunctional antimicrobial peptides: therapeutic targets in several human diseases. J Mol Med. 2007;85:317–329
  31. Cotter PD, Hill C, Ross RP. Bacteriocins: developing innate immunity for food. Nat Rev Microbiol. 2005;3:777–788
  32. Brumfitt W, Salton MR, Hamiliton-Miller JM. Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. J Antimicrob Chemother. 2002;50:731–734
  33. Davies EA, Bevis HE, Delves-Broughton J. The use of the bacteriocin, nisin, as a preservative in ricotta-type cheeses to control the food-borne pathogen Listeria monocytogenes. Lett Appl Microbiol. 1997;24:343–346
  34. Severina E, Severin A, Tomasz A. Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens. J Antimicrob Chemother. 1998;41:341–347
  35. Rea MC, Clayton E, O’Connor P, Shanahan F, Kiely B, Ross RP, et al. Antimicrobial activity of lacticin 3147 against clinical Clostridium difficile strains. J Med Microbiol. 2007;56:940–946
  36. Galvin M, Hill C, Ross RP. Lacticin 3147 displays activity in buffer against Gram-positive bacterial pathogens which appear insensitive in standard plate assays. Lett Appl Microbiol. 1999;28:355–358
  37. Wanger A, Mills K. Testing of Mycobacterium tuberculosis susceptibility to ethambutol, isoniazid, rifampin, and streptomycin by using Etest. J Clin Microbiol. 1996;34:1672–1676
  38. Heifets LB, Iseman MD, Lindholm-Levy PJ. Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1996;40:2483–2487
  39. Sosunov V, Mischenko V, Eruslanov B, Svetoch E, Shakina Y, Stern N, et al. Antimycobacterial activity of bacteriocins and their complexes with liposomes. J Antimicrob Chemother. 2007;59:919–925

PII: S0924-8579(10)00163-9

doi: 10.1016/j.ijantimicag.2010.03.029

International Journal of Antimicrobial Agents
Volume 36, Issue 2 , Pages 132-136 , August 2010

Article Tools

* Image Usage & Resolution